Uncategorized
Spatial Atlasing: Why Sensitivity Is the Real Frontier
Sponsored content brought to you by
Cell atlasing efforts rest on a deceptively simple premise: To understand a tissue, you must find every cell in it, including the rare populations and transitional states whose biology is often the most clinically meaningful.
This is where atlasing gets hard. Throughput is no longer the bottleneck. Sensitivity is. A platform that captures only a fraction of transcripts per cell fails to detect lower-abundance populations that define an atlas’s resolution and utility.
A liver atlas that rewrites human zonation
A recent Nature study by Yakubovsky and colleagues at the Weizmann Institute illustrates what sensitivity makes possible. They built a spatial atlas of the healthy human liver from live donors, avoiding the transcriptomic distortions of deceased or adjacent-normal tissue, and used the MERSCOPE® Platform with a 500-gene panel to validate cellular zonation at single-molecule resolution.
What they found reshapes a long-standing model of liver biology. Hepatocyte functions long thought to be periportal in mammals, key urea cycle enzymes (OTC, NAGS, ASL), the gluconeogenic gene PCK2, and the master transcription factor HNF4A, are pericentrally zonated in humans. Kupffer cell localization is also inverted relative to mouse: in humans, these macrophages are enriched in the pericentral zone. None of this would have surfaced without high-sensitivity spatial transcriptomics.
“MERSCOPE allowed us to validate zonation programs at single-molecule resolution. That sensitivity was essential to a reference atlas we could trust,” said Shalev Itzkovitz, PhD, an assistant professor at Weizmann Institute of Science and lead author on the Nature paper.
MERFISH 2.0
: built for the cells that might be missed
MERFISH 2.0 offers improvements to per-cell transcript capture and signal-to-noise that expand the dynamic range over which low-abundance transcripts and rare cell types become reliably detected. Early disease states, transitional progenitors, sparse immune subsets, and niche stromal cells move firmly into the resolved fraction of the atlas.
“When we set the design goals for MERFISH 2.0, the question we kept coming back to was: what are users still missing? Throughput wasn’t the answer, sensitivity was. Lowly expressed genes, and rare cells are where the most important biology often lives, and MERFISH 2.0 makes sure that rare events stop being the ones that get away,” said Jiang He, PhD, Co-founder and VP of Reagents, Vizgen.
Why MERSCOPE Ultra
Platform is the spatial atlas platform
Besides sensitivity, atlases also require tissue areas large enough to capture biological context and analytical flexibility to interpret what is found. Four capabilities of the MERSCOPE Ultra Platform combine to produce atlas-grade data:
Three cm² imaging area. Larger sections, multi-region samples, and cohort-scale studies without registration artifacts or sampling bias.
MERFISH 2.0 sensitivity. MERFISH 2.0 ensures rare populations and rare transcripts are accurately resolved.
Tissue clearing. Many informative atlasing tissues, liver, brain, dense tumor samples, are optically challenging. Clearing reduces autofluorescence and scattering, preserving single-molecule signal across the full section thickness.
Customizable segmentation and analysis. MERSCOPE’s pipeline lets researchers tune cell boundary detection and adapt clustering to the biology.

Getting to MERFISH 2.0 quickly
MERSCOPE Pre-designed Panels with Add-on capabilities give researchers a direct path: Existing instruments remain compatible, and labs can apply the enhanced chemistry to projects already in progress. More than 20 validated Pre-designed Panels span human biology, oncology, and dedicated mouse studies.
The atlasing moment
The Human Cell Atlas and disease-focused atlasing efforts are moving from pilot to production scale, and the atlases built now will be cited and expanded on for years. The question is whether a platform finds the cells that matter most: the ones that change everything when you finally see them.
“Cell atlases need more than cell-type identity. Spatial technologies like the MERSCOPE Platform are how we add location and function to that picture, and that context is what makes an atlas useful for understanding tissue biology, not just cataloguing it,” said Liat Alyagor, PhD, head of immunohistochemistry, Weizmann Institute of Science.
That is the standard MERSCOPE Ultra was built to meet.

Learn more vizgen.com.
The post Spatial Atlasing: Why Sensitivity Is the Real Frontier appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.
The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”
The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”
Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.
The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”
Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.
“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”
“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”
The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Uncategorized
An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
